Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023835 · ClinicalTrials.gov registry record · Phase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Zydus Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT07023835: Active Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Zydus Therapeutics.
NCT07023835 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that is active but no longer recruiting, run by Zydus Therapeutics. The registered enrollment target is 240 participants, below the 289-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (17% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07023835, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), is active but no longer recruiting, sponsored by Zydus Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Primary Outcome
Change in disease progression from baseline through Week 36 as measured by ALSFRS-R total score
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 50 mg Usnoflast
- DRUG 75 mg Usnoflast
Study Locations (17)
California
- Zydus US015 - La Jolla
- Zydus US008 - Orange
- Zydus US013 - San Francisco
Texas
- Zydus US001 - Dallas
- Zydus US002 - Houston
Connecticut
- Zydus US005 - New Britain
Florida
- Zydus US012 - Tampa
Georgia
- Zydus US007 - Atlanta
Massachusetts
- Zydus US010 - Boston
Michigan
- Zydus US006 - Detroit
Nebraska
- Zydus US014 - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What the registry record for NCT07023835 still lists
NCT07023835 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 289-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07023835 lists 17 locations in 14 states (California, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07023835 about?
NCT07023835 is a clinical study titled "Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis". Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
What is the current status of trial NCT07023835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-09-17. Estimated completion is 2028-10.
What conditions does trial NCT07023835 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT07023835?
The interventions under investigation include: Placebo (DRUG), 50 mg Usnoflast (DRUG), 75 mg Usnoflast (DRUG).
Who is sponsoring clinical trial NCT07023835?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023835 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07023835's enrollment target sits among peer trials
240 5th of 18 higher than 14 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI